The estimated Net Worth of Stuart J Swiedler is at least $2.42 Million dollars as of 1 July 2008. Stuart Swiedler owns over 15,000 units of Biomarin Pharmaceutical stock worth over $2,119,500 and over the last 20 years Stuart sold BMRN stock worth over $300,000.
Stuart has made over 11 trades of the Biomarin Pharmaceutical stock since 2005, according to the Form 4 filled with the SEC. Most recently Stuart exercised 15,000 units of BMRN stock worth $91,950 on 1 July 2008.
The largest trade Stuart's ever made was selling 30,000 units of Biomarin Pharmaceutical stock on 21 November 2005 worth over $300,000. On average, Stuart trades about 9,118 units every 56 days since 2005. As of 1 July 2008 Stuart still owns at least 25,000 units of Biomarin Pharmaceutical stock.
You can see the complete history of Stuart Swiedler stock trades at the bottom of the page.
Stuart's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO, CA, 94949.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy, and Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: